Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (133)	12/6/1997 10:19:00 AM
From: r. peter Dale	Read Replies (1) \| Respond to of 579

Altering secretase activity is correlated with changed patterns of Aá deposition. Mutant presenilin activity is also crucial for APP cleavage to the 1-40 peptide. These are circumstantial factors, mostly pertaining to the small subset of FAD cases (e.g., non-sporadic) where the risk factors are better understood yet the underlying causal roots or constellation of events are unknown. Identifying the underlying mechanisms of AD leading to the organic loss is a monumental task; the Sibia/BMY secretase program examines one candidate participant that may or may not address the underlying organic loss. A paper suggesting Tacrine has anti-Aá activty independent of its anti-AchE role. ncbi.nlm.nih.gov Best wishes, Peter